Document is current
Any future updates will be listed below
-
Authors
Gillesberg, Frederik S. https://orcid.org/0000-0002-8082-1831
Pehrsson, Martin https://orcid.org/0000-0002-4787-5563
Bay-Jensen, Anne-Christine https://orcid.org/0000-0001-7952-9297
Frederiksen, Peder
Karsdal, Morten https://orcid.org/0000-0001-5026-8740
Deleuran, Bent W. https://orcid.org/0000-0002-7079-1587
Kragstrup, Tue W. https://orcid.org/0000-0002-6439-397X
Kubo, Satoshi https://orcid.org/0000-0001-9693-9263
Tanaka, Yoshiya https://orcid.org/0000-0002-0807-7139
Mortensen, Joachim H. https://orcid.org/0000-0003-0326-7264
-
Funding
Funding for this research was provided by:
Innovation Fund Denmark (1044-00131B)
Innovation Fund Denmark (1044-00131B)
Innovation Fund Denmark (1044-00131B)
Innovation Fund Denmark (1044-00131B)
Innovation Fund Denmark (1044-00131B)
- License Information
-
More Information
Article History
Received: 15 August 2024
Accepted: 20 December 2024
First Online: 7 January 2025
Declarations
:
: Martin Pehrsson, Anne-Christine Bay-Jensen, Morten Karsdal, Peder Frederiksen and Joachim H. Mortensen are employees at Nordic Bioscience, Denmark. Nordic Bioscience is a biotechnology company doing contract research with the pharmaceutical industry. Anne-Christine Bay-Jensen and Morten Karsdal own stock in Nordic Bioscience. The biomarker assays PRO-C1, PRO-C3, PRO-C6, FBN-C and C3M are proprietary intellectual property of Nordic Bioscience. Frederik S. Gillesberg, Bent W. Deleuran, Tue W. Kragstrup, Satoshi Kubo and Yoshiya Tanaka have no competing interests in relation to this work.
